Business
Bruker Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin
The Avance® 1.2 GHz NMR system will enable advanced studies of biomolecular structures and function in structural biology, pharmacology, and cellular biology
About this update from Bruker Corporation
[{"type":"text","content":"\nThe Avance® 1.2 GHz NMR system will enable advanced studies of biomolecular structures and function in structural biology, pharmacology, and cellular biology\n\n\n BERLIN--(BUSINESS WIRE)--\nBruker Corporation (Nasdaq: BRKR) is pleased to announce the successful installation of a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in the second quarter of 2024. This ultra-high field NMR system positions FMP among leading institutions worldwide with access to 1.2 GHz NMR, enabling breakthrough biomolecular research.\n\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240702500630/en/New 1.2 GHz Avance® NMR system at Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin (Photo: Business Wire)\nUltra-high field NMR is a vital tool in pharmacology research, providing unique insights into molecular dynamics and structural rearrangements related to drug-target binding, protein interactions, and macromolecular structure refinements and rearrangements. Intrinsically disordered proteins (IDPs) play key roles in cell biology, such as IDPs implicated in cancer and infectious diseases. IDPs can be studied in depth using GHz-class NMR, by taking advantage of increased resolution of 1.2 GHz NMR. Researchers can gain an understanding of the conformational dynamics and function of IDPs to unlock the secrets of these important proteins and their role in diseases. This makes 1.2 GHz NMR a powerful tool for advancing our understanding of cellular and disease biology, and the development of therapies.\n\n\nThe Leibniz Forschungsinstitut für Molekulare Pharmakologie is a respected research institute committed to advancing the field of molecular pharmacology through groundbreaking research and innovation. Since 1995, the institute has integrated eleven NMR systems, including the recently installed 1.2 GHz AVANCE® NMR spectrometer. Dr. Peter Schmieder, Head of FMP's NMR platform, stated: \"At FMP, we have witnessed the evolution of NMR over almost 30 years, with each step forward bringing new research opportunities. The 1.2 GHz instrument is the next step and we are excited about the new opportunities.”\n\n\nProfessor Hartmut Oschkinat, whose scientific work and persistence were essential for the realization of the 1.2 ...